Shots:

• ELIAS Animal Health is planning to commence clinical evaluation of its T-cell therapy, ELIAS Cancer Immunotherapy (ECI), combined with a new adj., as a limb-sparing treatment of appendicular osteosarcoma in large-breed dogs
• The study will explore new treatment possibilities with the combination that may avoid amputation, enhancing the quality of life in dogs. ECI has also shown favorable outcomes in prior canine osteosarcoma trials and reached a milestone in product licensure
• The study will be carried out in partnership with Dr. Jeffrey Bryan and Dr. Megan Mickelson at the University of Missouri plus will be sponsored by a grant from the Morris Animal Foundation

Ref: PR Newswire | Image: ELIAS Animal Health

Related News:- ELIAS Animal Health Reports Results from the (ECI-OSA-04) Study of ELIAS Cancer Immunotherapy (ECI) for Treating Bone Cancer in Dogs

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com